Get started
Author

Jodie Pang

The Identification of 2-(1 H -Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2- d ]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer
2008 · Adrian J. Folkes, Khatereh Ahmadi, et al. · Journal of Medicinal Chemistry · 740
Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition
2016 · Aaron Boudreau, Hans E Purkey, et al. · Nature Chemical Biology · 278
GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway
2011 · Jeffrey J. Wallin, Kyle A. Edgar, et al. · Molecular Cancer Therapeutics · 229
Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer
2011 · Daniel P. Sutherlin, Linda Bao, et al. · Journal of Medicinal Chemistry · 219
Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity
2013 · Chudi O. Ndubaku, Timothy P. Heffron, et al. · Journal of Medicinal Chemistry · 179
Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα
2022 · Emily J. Hanan, Marie-Gabrielle Braun, et al. · Journal of Medicinal Chemistry · 159
Discovery of (Thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer
2010 · Daniel P. Sutherlin, Deepak Sampath, et al. · Journal of Medicinal Chemistry · 133
Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR
2016 · Timothy P. Heffron, Chudi O. Ndubaku, et al. · ACS Medicinal Chemistry Letters · 110
PDF
The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of ( S )-2-((2-(1-Isopropyl-1 H -1,2,4-triazol-5-yl)-5,6-dihydrobenzo[ f ]imidazo[1,2- d ][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326)
2016 · Timothy P. Heffron, Robert A. Heald, et al. · Journal of Medicinal Chemistry · 106
Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor
2010 · Timothy P. Heffron, Megan Berry, et al. · Bioorganic & Medicinal Chemistry Letters · 90
Selective NaV1.7 Antagonists with Long Residence Time Show Improved Efficacy against Inflammatory and Neuropathic Pain
2018 · Girish Bankar, Samuel J. Goodchild, et al. · Cell Reports · 77
PDF
Discovery of Aryl Sulfonamides as Isoform-Selective Inhibitors of NaV1.7 with Efficacy in Rodent Pain Models
2016 · Thilo Focken, Shifeng Liu, et al. · ACS Medicinal Chemistry Letters · 72
Targeting the PI3K Pathway in the Brain—Efficacy of a PI3K Inhibitor Optimized to Cross the Blood–Brain Barrier
2012 · Laurent Salphati, Timothy P. Heffron, et al. · Clinical Cancer Research · 70
Discovery of Novel PI3-Kinase δ Specific Inhibitors for the Treatment of Rheumatoid Arthritis: Taming CYP3A4 Time-Dependent Inhibition
2012 · Brian S. Safina, Stewart Baker, et al. · Journal of Medicinal Chemistry · 66
Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma
2019 · Sarah M. Bronner, Karl A. Merrick, et al. · Bioorganic & Medicinal Chemistry Letters · 65
Potent and Highly Selective Benzimidazole Inhibitors of PI3-Kinase Delta
2012 · Jeremy M. Murray, Zachary K. Sweeney, et al. · Journal of Medicinal Chemistry · 65
Cell Active Hydroxylactam Inhibitors of Human Lactate Dehydrogenase with Oral Bioavailability in Mice
2016 · Hans E. Purkey, Kirk Robarge, et al. · ACS Medicinal Chemistry Letters · 59
The Design and Identification of Brain Penetrant Inhibitors of Phosphoinositide 3-Kinase α
2012 · Timothy P. Heffron, Laurent Salphati, et al. · Journal of Medicinal Chemistry · 54
Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma
2016 · Laurent Salphati, Bruno Alicke, et al. · Drug Metabolism and Disposition · 52
Potent and selective inhibitors of PI3Kδ: Obtaining isoform selectivity from the affinity pocket and tryptophan shelf
2012 · Daniel P. Sutherlin, Stewart Baker, et al. · Bioorganic & Medicinal Chemistry Letters · 52
Nonselective inhibition of the epigenetic transcriptional regulator BET induces marked lymphoid and hematopoietic toxicity in mice
2016 · Dong U. Lee, Paula Katavolos, et al. · Toxicology and Applied Pharmacology · 47
Distribution of the Phosphatidylinositol 3-Kinase Inhibitors Pictilisib (GDC-0941) and GNE-317 in U87 and GS2 Intracranial Glioblastoma Models—Assessment by Matrix-Assisted Laser Desorption Ionization Imaging
2014 · Laurent Salphati, Sheerin Shahidi-Latham, et al. · Drug Metabolism and Disposition · 46
Discovery of Spiro-azaindoline Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1)
2021 · Bryan K. Chan, Eileen Seward, et al. · ACS Medicinal Chemistry Letters · 43
Discovery of Acyl-sulfonamide Nav1.7 Inhibitors GDC-0276 and GDC-0310
2021 · Brian S. Safina, Steven J. McKerrall, et al. · Journal of Medicinal Chemistry · 43
Evaluation of Organic Anion Transporting Polypeptide 1B1 and 1B3 Humanized Mice as a Translational Model to Study the Pharmacokinetics of Statins
2014 · Laurent Salphati, Xiaoyan Chu, et al. · Drug Metabolism and Disposition · 43
Works count: 107
Citation count: 3,820
H-index: 31
I10-index: 50
Year
Topic
Type